Drug
Spn 810
Spn 810: highest development phase Phase 3, developed by Supernus Pharmaceuticals. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Supernus Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| SPN-810 (18 mg) NCT02618434 | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) |
| SPN-810 (18 mg) NCT02618408 | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) |
| SPN-810 NCT03597503 | Phase 3 | Attention Deficit Hyperactivity Disorder |
| SPN-810 NCT01364662 | Phase 2 | Impulsive Aggression Comorbid With ADHD |
| SPN-810 NCT00626236 | Phase 2 | Attention Deficit Disorder With Hyperactivity |
Latest
No recent events.
Follow Spn 810 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.